HICC: Humoral Immune Correlates for COVID19: Defining protective responses and critical readouts for Clinical Trials of Vaccines and Therapeutics | Pandemic PACT Tracker

Key facts

Disease
COVID-19
Start & end year
2020
2022
Known Financial Commitments (USD)
$1,921,735.46
Funder
Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR)
Principal Investigator
N/A
Research Location
United Kingdom
Lead Research Institution
University of Cambridge
Research Priority Alignment
N/A

Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified

Abstract

Not Available

28 Publications linked via Europe PMC

Last Updated:6 days ago

View all publications at Europe PMC

Activation of the Lectin Pathway Drives Persistent Complement Dysregulation in Long COVID.

Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection.

Differential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies.

SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.

Authors
Liew F, Talwar S, Cross A, Willett BJ, Scott S, Logan N, Siggins MK, Swieboda D, Sidhu JK, Efstathiou C, Moore SC, Davis C, Mohamed N, Nunag J, King C, Thompson AAR, Rowland-Jones SL, Docherty AB, Chalmers JD, Ho LP, Horsley A, Raman B, Poinasamy K, Marks M, Kon OM, Howard L, Wootton DG, Dunachie S, Quint JK, Evans RA, Wain LV, Fontanella S, de Silva TI, Ho A, Harrison E, Baillie JK, Semple MG, Brightling C, Thwaites RS, Turtle L, Openshaw PJM, ISARIC4C Investigators, PHOSP-COVID collaborative group.
Publish Year
2023
Journal
EBioMedicine
DOI
10.1016/j.ebiom.2022.104402

View at Europe PMC

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies.

Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected patients.

Human seasonal coronavirus neutralization and COVID-19 severity.

Inhibition of the lectin pathway of complement ameliorates hypocomplementemia and restores serum bactericidal activity in patients with severe COVID-19.

Secondary Complement Deficiency Impairs Anti-Microbial Immunity to Klebsiella pneumoniae and Staphylococcus aureus During Severe Acute COVID-19.